Neuropathy as a potential complication of levodopa use in Parkinson's disease

Movement Disorders

Volumn 23, Issue 13, 2008, Pages 1850-1859

  Toth, Cory ^a   Brown, Martin Sutton ^a   Furtado, Sarah ^a   Suchowersky, Oksana ^a   Zochodne, Douglas ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Cobalamin; Homocysteine; Levodopa; Methylmalonic acid; Parkinson's disease; Peripheral neuropathy

Indexed keywords

AMANTADINE; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; CYANOCOBALAMIN; DOPAMINE RECEPTOR STIMULATING AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; HOMOCYSTEINE; METFORMIN; METHYLMALONIC ACID; MULTIVITAMIN; PROTON PUMP INHIBITOR;

AMINO ACID BLOOD LEVEL; ARTICLE; BRAIN DEPTH STIMULATION; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CYANOCOBALAMIN DEFICIENCY; DIABETES MELLITUS; DIET RESTRICTION; DISEASE SEVERITY; DOSE RESPONSE; DRUG USE; HUMAN; PALLIDOTOMY; PARKINSON DISEASE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; TREATMENT DURATION; VITAMIN BLOOD LEVEL; VITAMIN METABOLISM;

ANALYSIS OF VARIANCE; ANTIPARKINSON AGENTS; FEMALE; HOMOCYSTEINE; HUMANS; LEVODOPA; MALE; METHYLMALONIC ACID; PARKINSON DISEASE; PERIPHERAL NERVOUS SYSTEM DISEASES; RETROSPECTIVE STUDIES; VITAMIN B 12;

EID: 57049093277     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22137     Document Type: Article

References (40)

1. Khan NL, Graham E, Critchley P, et al. Parkin disease: a phenotypic study of a large case series. Brain 2003;126:1279-1292.
2. Postuma RB, Lang AE. Homocysteine and levodopa: should Parkinson disease patients receive preventative therapy? Neurology 2004;63:886-891.
3. Saperstein DS, Wolfe GI, Gronseth GS, et al. Challenges in the identification of cobalamin-deficiency polyneuropathy. Arch Neurol 2003;60:1296-1301.
4. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002; 288:2015-2022.
5. Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002;346:476-483.
6. Rajput AH, Stern W, Laverty WH. Chronic low-dose levodopa therapy in Parkinson's disease: an argument for delaying levodopa therapy. Neurology 1984;34:991-996.
7. Bril V, Perkins BA. Validation of the Toronto clinical scoring system for diabetic polyneuropathy. Diabetes Care 2002;25:2048-2052.
8. Nicolas G, Maisonobe T, Le FN, Leger JM, Bouche P. Proposed revised electrophysiological criteria for chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 2002;25: 26-30.
9. Healton EB, Savage DG, Brust JC, Garrett TJ, Lindenbaum J. Neurologic aspects of cobalamin deficiency. Medicine (Baltimore) 1991;70:229-245.
10. McCombe PA, McLeod JG. The peripheral neuropathy of vitamin B12 deficiency. J Neurol Sci 1984;66:117-126.
11. Fine EJ, Soria E, Paroski MW, Petryk D, Thomasula L. The neurophysiological profile of vitamin B12 de.ciency. Muscle Nerve 1990;13:158-164.
12. Roy MK. Familial parkinsonism with peripheral neuropathy. J Assoc Physicians India 2001;49:944.
13. Rohatgi A, Kulshrestha M, Sachdeva S. Familial parkinsonism with peripheral neuropathy. J Assoc Physicians India 2000;48: 752-753.
14. Abbruzzese G, Pigullo S, Schenone A, et al. Does parkin play a role in the peripheral nervous system? A family report. Mov Disord 2004;19:978-981.
15. Okuma Y, Hattori N, Mizuno Y. Sensory neuropathy in autosomal recessive juvenile parkinsonism (PARK2). Parkinsonism Relat Disord 2003;9:313-314.
16. Chand RP, Tharakan JK, Koul RL, Kumar SD. Clinical and radiological features of juvenile onset olivopontocerebellar atrophy. Clin Neurol Neurosurg 1996;98:152-156.
17. Rossi A, Ciacci G, Federico A, Mondelli M, Rizzuto N. Sensory and motor peripheral neuropathy in olivopontocerebellar atrophy. Acta Neurol Scand 1986;73:363-371.
18. Luoma P, Melberg A, Rinne JO, et al. Parkinsonism, premature menopause, and mitochondrial DNA polymerase gamma mutations: clinical and molecular genetic study. Lancet 2004;364: 875-882.
19. Lindenbaum J, Savage DG, Stabler SP, Allen RH. Diagnosis of cobalamin deficiency. II. Relative sensitivities of serum cobalamin, methylmalonic acid, and total homocysteine concentrations. Am J Hematol 1990;34:99-107.
20. Savage DG, Lindenbaum J, Stabler SP, Allen RH. Sensitivity of serum methylmalonic acid and total homocysteine determinations for diagnosing cobalamin and folate deficiencies. Am J Med 1994;96:239-246.
21. Green R, Kinsella LJ. Current concepts in the diagnosis of cobalamin deficiency. Neurology 1995;45:1435-1440.
22. Lawrence de Koning AB, Werstuck GH, Zhou J, Austin RC. Hyperhomocysteinemia and its role in the development of atherosclerosis. Clin Biochem 2003;36:431-441.
23. Snow CF. Laboratory diagnosis of vitamin B12 and folate deficiency: a guide for the primary care physician. Arch Intern Med 1999;159:1289-1298.
24. Blandini F, Fancellu R, Martignoni E, et al. Plasma homocysteine and L-dopa metabolism in patients with Parkinson disease. Clin Chem 2001;47:1102-1104.
25. Kuhn W, Roebroek R, Blom H, van OD, Muller T. Hyperhomo-cysteinaemia in Parkinson's disease. J Neurol 1998;245:811-812.
26. Kuhn W, Roebroek R, Blom H, et al. Elevated plasma levels of homocysteine in Parkinson's disease. Eur Neurol 1998;40:225-227.
27. Yasui K, Kowa H, Nakaso K, Takeshima T, Nakashima K. Plasma homocysteine and MTHFR C677T genotype in levodopatreated patients with PD. Neurology 2000;55:437-440.
28. Muller T, Werne B, Fowler B, Kuhn W. Nigral endothelial dysfunction, homocysteine, and Parkinson's disease. Lancet 1999; 354:126-127.
29. Rogers JD, Sanchez-Saffon A, Frol AB, az-Arrastia R. Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease. Arch Neurol 2003;60:59-64.
30. Miller JW, Selhub J, Nadeau MR, Thomas CA, Feldman RG, Wolf PA. Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status. Neurology 2003;60: 1125-1129.
31. Miller JW, Shukitt-Hale B, Villalobos-Molina R, Nadeau MR, Selhub J, Joseph JA. Effect of L-Dopa and the catechol-O-methyltransferase inhibitor Ro 41-0960 on sulfur amino acid metabolites in rats. Clin Neuropharmacol 1997;20:55-66.
32. Daly D, Miller JW, Nadeau MR, Selhub J. The effect of L-dopa administration and folate deficiency on plasma homocysteine concentration in rats. Nutr Biochem 1997;8:634-640.
33. O'Suilleabhain PE, Bottiglieri T, Dewey RB, Jr, Sharma S, azArrastia R. Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease. Mov Disord 2004;19: 1403-1408.
34. Yasui K, Nakaso K, Kowa H, Takeshima T, Nakashima K. Levodopa-induced hyperhomocysteinaemia in Parkinson's disease. Acta Neurol Scand 2003;108:66-67.
35. Postuma RB, Espay AJ, Zadikoff C, et al. Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study. Neurology 2006;66:1941-1943.
36. Ostrem JL, Kang GA, Subramanian I, et al. The effect of entacapone on homocysteine levels in Parkinson disease. Neurology 2005;64:1482.
37. Zoccolella S, Lamberti P, Armenise E, et al. Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications. Parkinsonism Relat Disord 2005;11:131-133.
38. Lamberti P, Zoccolella S, Armenise E, et al. Hyperhomocysteinemia in L-dopa treated Parkinson's disease patients: effect of cobalamin and folate administration. Eur J Neurol 2005;12:365-368.
39. Valkovic P, Benetin J, Blazicek P, Valkovicova L, Gmitterova K, Kukumberg P. Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients. Parkinsonism Relat Disord 2005;11:253-256.
40. Hughes RA. Peripheral neuropathy. BMJ 2002;324:466-469.